Spero Therapeutics, Inc. (SPRO) stock
SPRONasdaqPharmaceutical PreparationsFiscal year ends December 31
$1.00−0.02 (-1.96%)
Close on Nov 12, 2026Market cap $58.23MP/E –Yield –
Spero Therapeutics profit margin
Profit margin (net margin) is net income as a percentage of revenue.
Spero Therapeutics's profit margin for the twelve months ending Sep 30, 2026 was -71.0%. For fiscal 2025 it was 12.8%, against -142.9% the year before. The highest annual figure on record is 22.0% in fiscal 2023.
Annual profit margin
| Period | Period end | Value | Change (pts) |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | 12.8% | +155.7 |
| FY2024 | Dec 31, 2024 | -142.9% | −164.9 |
| FY2023 | Dec 31, 2023 | 22.0% | +513.9 |
| FY2021 | Dec 31, 2021 | -491.9% | +347.3 |
| FY2020 | Dec 31, 2020 | -839.2% | −503.6 |
| FY2019 | Dec 31, 2019 | -335.6% | +715.8 |
| FY2018 | Dec 31, 2018 | -1051.4% | +906.3 |
| FY2017 | Dec 31, 2017 | -1957.7% | +5651.5 |
| FY2016 | Dec 31, 2016 | -7609.3% | – |
Quarterly profit margin
Change is against the same quarter a year earlier.
| Period | Period end | Value | Change (pts) |
|---|---|---|---|
| Q1 FY2026 | Mar 31, 2026 | -2791.9% | −2555.8 |
| Q4 FY2025 | Dec 31, 2025 | 76.3% | +215.2 |
| Q3 FY2025 | Sep 30, 2025 | -135.6% | −8.3 |
| Q2 FY2025 | Jun 30, 2025 | -12.0% | +163.2 |
| Q1 FY2025 | Mar 31, 2025 | -236.1% | −99.3 |
| Q4 FY2024 | Dec 31, 2024 | -138.8% | −208.5 |
| Q3 FY2024 | Sep 30, 2024 | -127.3% | −114.7 |
| Q2 FY2024 | Jun 30, 2024 | -175.2% | +263.0 |
| Q1 FY2024 | Mar 31, 2024 | -136.7% | +506.1 |
| Q4 FY2023 | Dec 31, 2023 | 69.6% | +652.9 |
| Q3 FY2023 | Sep 30, 2023 | -12.6% | +1427.5 |
| Q2 FY2023 | Jun 30, 2023 | -438.1% | +1147.2 |
| Q1 FY2023 | Mar 31, 2023 | -642.8% | +425.0 |
| Q3 FY2022 | Sep 30, 2022 | -583.3% | +151.1 |
| Q2 FY2022 | Jun 30, 2022 | -1440.0% | −1078.7 |
| Q1 FY2022 | Mar 31, 2022 | -1585.3% | −1319.6 |
| Q4 FY2021 | Dec 31, 2021 | -1067.8% | −92.4 |
| Q3 FY2021 | Sep 30, 2021 | -734.3% | −261.2 |
| Q2 FY2021 | Jun 30, 2021 | -361.3% | +652.0 |
| Q1 FY2021 | Mar 31, 2021 | -265.8% | +1104.0 |
| Q4 FY2020 | Dec 31, 2020 | -975.4% | +2616.6 |
| Q3 FY2020 | Sep 30, 2020 | -473.1% | −91.9 |
| Q2 FY2020 | Jun 30, 2020 | -1013.3% | −401.1 |
| Q1 FY2020 | Mar 31, 2020 | -1369.8% | −1303.7 |
| Q4 FY2019 | Dec 31, 2019 | -3592.0% | −2963.3 |
| Q3 FY2019 | Sep 30, 2019 | -381.2% | +1208.9 |
| Q2 FY2019 | Jun 30, 2019 | -612.2% | +1538.1 |
| Q1 FY2019 | Mar 31, 2019 | -66.1% | +857.1 |
| Q4 FY2018 | Dec 31, 2018 | -628.7% | +767.3 |
| Q3 FY2018 | Sep 30, 2018 | -1590.1% | +57.4 |
| Q2 FY2018 | Jun 30, 2018 | -2150.3% | +1532.0 |
| Q1 FY2018 | Mar 31, 2018 | -923.2% | +3274.0 |
| Q4 FY2017 | Dec 31, 2017 | -1396.0% | – |
| Q3 FY2017 | Sep 30, 2017 | -1647.6% | – |
| Q2 FY2017 | Jun 30, 2017 | -3682.3% | – |
| Q1 FY2017 | Mar 31, 2017 | -4197.1% | – |
See a number that looks wrong?